Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$1.97 - $3.69 $309,053 - $578,887
156,880 New
156,880 $503,000
Q3 2020

Nov 13, 2020

SELL
$1.59 - $2.19 $1,931 - $2,660
-1,215 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$1.05 - $2.18 $1,275 - $2,648
1,215 New
1,215 $2,000

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $1.34B
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track Lazard Asset Management LLC Portfolio

Follow Lazard Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.